| abstract |
The invention belongs to the technical field of medicines, and relates to a compound with structural characteristics of a formula (I), wherein R1, R2, X1, X2, Cy1, m and n are defined in the specification, the compound and pharmaceutically acceptable salts, isomers, prodrug cocrystal complexes, hydrates and solvates thereof can be used for inhibiting retinoic acid-related orphan receptor gamma (ROR gamma), and preventing or treating ROR gamma-mediated inflammation, metabolism, autoimmunity and other diseases or symptoms such as psoriasis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, asthma, lupus erythematosus, autoimmune hepatitis or type I and type II diabetes, and have the characteristics of high efficiency, low toxicity and good metabolic stability. (Ⅰ)。 |